Drug Detail:Methsuximide (Methsuximide [ meth-sux-i-mide ])
Drug Class: Succinimide anticonvulsants
Usual Adult Dose for Seizures
Initial dose: 300 mg orally once a day for the first week
- If needed, increase the daily dosage in increments of 300 mg/day at weekly intervals
Comments:
- The above dosing is suggested, however, because therapeutic effect and tolerance may vary among patients, therapy must be individualized according to the response of each patient.
- The optimal dose is the amount of drug which is barely sufficient to control seizures so that side effects may be kept to a minimum.
Use: For the control of absence (petit mal) seizures that are refractory to other drugs.
Usual Pediatric Dose for Seizures
Children:
Initial dose: 10 to 15 mg/kg/day orally in 3 to 4 divided doses
- May increase at weekly intervals
Comments:
- The above dosing is suggested, however, because therapeutic effect and tolerance may vary among patients, therapy must be individualized according to the response of each patient.
- The optimal dose is the amount of drug which is barely sufficient to control seizures so that side effects may be kept to a minimum.
Use: For the control of absence (petit mal) seizures that are refractory to other drugs.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
Hypersensitivity to succinimides
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Take orally
Storage requirements:
- Protect from light and moisture; protect from excessive heat (104F [40C])
General:
- Using this drug as monotherapy in patients with mixed type of epilepsy may increase the frequency of grand mal seizures in some patients.
- Abrupt withdrawal may precipitate seizures; as with other antiepileptic drugs, dose increases, and decreases should proceed slowly.
Monitoring:
- Blood counts, periodically, and if signs and/or symptoms of infection develop
- Urinalysis periodically
- Liver function tests periodically
- Monitor for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior
- Monitor for rash
Patient advice:
- Read the US FDA-approved patient labeling (Medication Guide).
- Patients should understand the importance of strictly adhering to their dosing regimen.
- Patients should be appropriately counseled regarding the performance of potentially hazardous tasks.
- Patients should be instructed to contact their healthcare provider promptly if they develop a rash or signs and symptoms of an infection.
- Patients and/or caregivers should monitor for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior; behaviors of concern should be reported promptly.
- Women of childbearing potential should speak with their physician if they are or intend to become pregnant or are breastfeeding.